Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?

Eur Respir J · 2017 · PMC5898951 · PMID 28572122

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

a strong trendp=0.066so close (0.05 < p ≤ 0.1)

In multivariate analyses overall survival for gemcitabine was superior to pemetrexed chemotherapy (HR 2.39, 95% CI 1.31–4.35; p=0.004) and a strong trend was observed compared to etoposide (1.54, 0.97–2.43; p=0.066) ( figure 3 ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.